Melane Sampson, Author at BioTuesdays

Developments

Firefly nears launch of NVIDIA-powered human brain model

Firefly Neuroscience (NASDAQ: AIFF) has announced a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes. Through its acquisition of closely held Evoke...

March 4, 2026

Developments

FDA approves Perimeter’s Claire, first AI imaging device for breast cancer surgery

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has received FDA premarket approval (PMA) for Claire—formerly the Perimeter OCT B-Series with ImgAssist AI 2.0—the first AI-enabled imaging...

March 3, 2026

Developments

Rein doses first patient in Phase 2 trial of LTI-03 in IPF

Rein Therapeutics (NASDAQ: RNTX) has announced that the first patient has been dosed in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with...

March 3, 2026

Feature

Casp-Aid targeting neuronal neurodegeneration to restore cognition in Alzheimer disease

Closely held Casp-Aid is advancing a differentiated therapeutic strategy aimed at repairing damaged neurons responsible for cognitive impairment by targeting the root cause of neuronal damage in Alzheimer disease (AD)...

March 3, 2026

Developments

AIM signs Phase 3 design deal for Ampligen in pancreatic cancer

AIM ImmunoTech (NYSE American: AIM) has announced the signing of an agreement with Thermo Fisher Scientific’s (NYSE: TMO) PPD clinical research business to design its Phase 3 clinical trial for Ampligen in the treatment...

March 2, 2026

Executive Moves

Prof. Joshua C. Brown joins NRx as CMO

NRx Pharmaceuticals (NASDAQ: NRXP) has announced the appointment of Prof. Joshua C. Brown, MD, PhD, as chief medical officer. Prof. Brown, a pioneer in understanding the biologic effect of Transcranial Magnetic...

March 2, 2026

Developments

Zomedica expands distribution with Moichor partnership

Zomedica (OTCQB: ZOMDF) has entered into a commercial distribution agreement with closely held Moichor, a veterinary reference and point-of-care laboratory service, to expand its distribution of TRUVIEW(R) digital...

February 25, 2026

Developments

Tiziana announces positive new biomarkers for nasal foralumab

Tiziana Life Sciences (NASDAQ: TLSA) has announced new biomarker data from a late-breaking poster presented by investigators from Brigham and Women’s Hospital, Boston, showing nasal foralumab downregulates cerebrospinal...

February 25, 2026

Feature

MediWound healing without surgery through a pineapple-derived enzymatic approach

MediWound (NASDAQ: MDWD) is advancing a proprietary enzymatic platform derived from bromelain, a proteolytic enzyme extracted from pineapple stems. The company’s non-surgical approach to necrotic tissue removal has...

February 24, 2026

Executive Moves

Foghorn appoints Ryan Maynard as CFO

Foghorn Therapeutics (NASDAQ: FHTX) has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today. Mr. Maynard brings more than 25 years of executive experience driving financial...

February 23, 2026

Author - Melane Sampson

Firefly nears launch of NVIDIA-powered human brain model

FDA approves Perimeter’s Claire, first AI imaging device for breast cancer surgery

Rein doses first patient in Phase 2 trial of LTI-03 in IPF

Casp-Aid targeting neuronal neurodegeneration to restore cognition in Alzheimer disease

AIM signs Phase 3 design deal for Ampligen in pancreatic cancer

Prof. Joshua C. Brown joins NRx as CMO

Zomedica expands distribution with Moichor partnership

Tiziana announces positive new biomarkers for nasal foralumab

MediWound healing without surgery through a pineapple-derived enzymatic approach

Foghorn appoints Ryan Maynard as CFO

Subscribe